---
layout: default
title: Metoprolol
description: "Metoprolol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 105
evidence_level: L1
indication_count: 10
---

# Metoprolol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Metoprololï¼šå¾ é«˜è¡€å£“ åˆ° æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šèˆ‡æ…¢æ€§è‚ºå¿ƒç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Metoprolol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Metoprololï¼ˆç¾æ‰˜æ™®æ´›ï¼‰æ˜¯ä¸€ç¨®é¸æ“‡æ€§ beta-1 è…ä¸Šè…ºç´ å—é«”é˜»æ–·åŠ‘ï¼Œç”¨æ–¼æ²»ç™‚é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡å’Œå¿ƒå¾‹ä¸æ•´ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š (malignant hypertensive renal disease)** å’Œ**æ…¢æ€§è‚ºå¿ƒç—… (chronic pulmonary heart disease)** æœ‰æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œç›®å‰æœ‰è¶…é **15 é …è‡¨åºŠè©¦é©—**æ”¯æŒæ…¢æ€§è‚ºå¿ƒç—…ç›¸é—œæ‡‰ç”¨ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ã€å¿ƒå®¤ä¸Šå¿ƒå¾‹ä¸æ•´ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | hypertensive disorderã€malignant hypertensive renal diseaseã€malignant renovascular hypertensionã€pulmonary hypertension owing to lung disease and/or hypoxiaã€pulmonary hypertension with unclear multifactorial mechanismã€Braddock syndromeã€myocardial infarctionã€posteroinferior myocardial infarctionã€posterolateral myocardial infarctionã€septal myocardial infarction |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.91% (æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š), 99.40% (æ…¢æ€§è‚ºå¿ƒç—…) |
| è­‰æ“šç­‰ç´š | L2 (æ…¢æ€§è‚ºå¿ƒç—…), L5 (æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 15+ å¼µ |
| å»ºè­°æ±ºç­– | Explore |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Metoprolol é€šéé¸æ“‡æ€§é˜»æ–·å¿ƒè‡Ÿ beta-1 å—é«”ï¼Œæ¸›å°‘å¿ƒç‡ã€å¿ƒè‚Œæ”¶ç¸®åŠ›å’Œå¿ƒè¼¸å‡ºé‡ï¼Œå¾è€Œé™ä½è¡€å£“å’Œå¿ƒè‚Œè€—æ°§é‡ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p><strong>æ…¢æ€§è‚ºå¿ƒç—…/COPD ç›¸é—œè©¦é©—ï¼š</strong></p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>ä¸»è¦ç ”ç©¶ç›®æ¨™</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT06825728</td>
<td>Phase 4</td>
<td>å°šæœªæ‹›å‹Ÿ</td>
<td>Metoprolol å° HFrEF åˆä½µ COPD æ‚£è€…çš„æ­»äº¡å’Œå†ä½é™¢å½±éŸ¿</td>
</tr>
<tr>
<td>NCT03370835</td>
<td>Phase 4</td>
<td>å®Œæˆ</td>
<td>æ¯”è¼ƒ Metoprolol å’Œ Carvedilol åœ¨ COPD æ‚£è€…çš„è€å—æ€§</td>
</tr>
<tr>
<td>NCT03778554</td>
<td>Phase 4</td>
<td>é€²è¡Œä¸­</td>
<td>å¿ƒè‚Œæ¢—å¡å¾Œç„¡å¿ƒè¡°æ‚£è€…çš„ beta-blocker æ²»ç™‚</td>
</tr>
<tr>
<td>NCT02587351</td>
<td>Phase 3</td>
<td>çµ‚æ­¢</td>
<td>Metoprolol é é˜² COPD æ€¥æ€§æƒ¡åŒ–</td>
</tr>
<tr>
<td>NCT03566667</td>
<td>Phase 4</td>
<td>é€²è¡Œä¸­</td>
<td>Beta-blocker å° COPD æ‚£è€…çš„ç›Šè™•</td>
</tr>
<tr>
<td>NCT00288548</td>
<td>Phase 4</td>
<td>æœªçŸ¥</td>
<td>Metoprolol èˆ‡ Formoterol åˆç”¨å° COPD è‚ºåŠŸèƒ½çš„å½±éŸ¿</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/8737105/">8737105</a></td>
<td>1996</td>
<td>RCT</td>
<td>Metoprolol vs Xamoterol å°å¿ƒè‚Œæ¢—å¡å¾Œå¿ƒè¡°æ‚£è€…å·¦å¿ƒåŠŸèƒ½çš„å½±éŸ¿</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/14711192/">14711192</a></td>
<td>2003</td>
<td>å‹•ç‰©ç ”ç©¶</td>
<td>ä¸åŒåŠ‘é‡ Carvedilol å’Œ Metoprolol é é˜²æ¢—å¡å¾Œå¿ƒå®¤é‡å¡‘çš„æ¯”è¼ƒ</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Braddock syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. posteroinferior myocardial infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. posterolateral myocardial infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. septal myocardial infarction</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ6 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8737105/" target="_blank">8737105</a></td><td>1996</td><td>Article</td><td>European heart journ</td><td>Effects of beta receptor antagonists on left ventricular fun...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14711192/" target="_blank">14711192</a></td><td>2003</td><td>Article</td><td>Japanese heart journ</td><td>Comparison of metoprolol with low, middle and high doses of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25446059/" target="_blank">25446059</a></td><td>2014</td><td>Article</td><td>Circulation</td><td>Explaining unexplained dyspnea: the ever &quot;holesome&quot; heart.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31770302/" target="_blank">31770302</a></td><td>2019</td><td>Article</td><td>JAAPA : official jou</td><td>Down syndrome, severe psoriasis, and increased risk for card...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6442004/" target="_blank">6442004</a></td><td>1984</td><td>Article</td><td>Scandinavian journal</td><td>Antianginal drug effects on normal, ischemic and scar myocar...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 1 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. chronic pulmonary heart disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ15 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06825728" target="_blank">NCT06825728</a></td><td>PHASE4</td><td>NOT_YET_RECRUITING</td><td>311</td><td>Metoprolol in Patients With Heart Failure With Reduced Ejection Fraction and Chr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04542785" target="_blank">NCT04542785</a></td><td>NA</td><td>RECRUITING</td><td>350</td><td>Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Dan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03370835" target="_blank">NCT03370835</a></td><td>PHASE4</td><td>COMPLETED</td><td>21</td><td>Randomized Open-Label Crossover Trial Comparing Tolerability of a Cardioselectiv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05580510" target="_blank">NCT05580510</a></td><td>PHASE2, PHASE3</td><td>UNKNOWN</td><td>160</td><td>&quot;An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empaglifloz...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03778554" target="_blank">NCT03778554</a></td><td>PHASE4</td><td>ACTIVE_NOT_RECRUITING</td><td>2760</td><td>Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduc...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 10 é …è©¦é©—</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. trichotillomania</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.05%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è£½å­—ç¬¬029301è™Ÿ | "æ˜å¾·"å¿ƒå£“æš¢éŒ 100æ¯«å…‹ | éŒ åŠ‘ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ |
| è¡›ç½²è—¥è£½å­—ç¬¬029313è™Ÿ | "æˆå¤§"è²ä»–å¯§éŒ 100æ¯«å…‹ | éŒ åŠ‘ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ |
| è¡›ç½²è—¥è£½å­—ç¬¬031032è™Ÿ | "å¥å–¬"å¿ƒèˆ’å¯§éŒ 100æ¯«å…‹ | éŒ åŠ‘ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ |

## å®‰å…¨æ€§è€ƒé‡

**ç¦å¿Œç—‡ï¼š**
- åš´é‡ç«‡æ€§å¿ƒå‹•éç·©
- äºŒæˆ–ä¸‰åº¦æˆ¿å®¤å‚³å°é˜»æ»¯
- å¿ƒæºæ€§ä¼‘å…‹
- å¤±ä»£å„Ÿæ€§å¿ƒè¡°
- åš´é‡å‘¨é‚Šå‹•è„ˆç–¾ç—…

**COPD æ‚£è€…æ³¨æ„äº‹é …ï¼š**
- é¸æ“‡æ€§ beta-1 é˜»æ–·åŠ‘ç›¸å°å®‰å…¨
- ä½åŠ‘é‡èµ·å§‹ï¼Œç·©æ…¢èª¿æ•´
- ç›£æ¸¬è‚ºåŠŸèƒ½å’Œå‘¼å¸ç—‡ç‹€
- æœ‰æ”¯æ°£ç®¡ç—™æ”£ç—…å²è€…è¬¹æ…ä½¿ç”¨

**è—¥ç‰©äº¤äº’ä½œç”¨ï¼š**
- Verapamil/Diltiazemï¼šå¢åŠ å¿ƒå‹•éç·©å’Œå‚³å°é˜»æ»¯é¢¨éšª
- Digoxinï¼šå¢å¼·å¿ƒå‹•éç·©æ•ˆæœ
- MAO æŠ‘åˆ¶åŠ‘ï¼šå¯èƒ½å¢å¼·é™å£“æ•ˆæœ
- Beta-agonist å¸å…¥åŠ‘ï¼šå¯èƒ½ç›¸äº’æ‹®æŠ—




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚

**é£Ÿç‰©** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©å¸æ”¶ã€‚å¯èƒ½å¢å¼·è—¥æ•ˆã€‚
- å»ºè­°ï¼šè«‹è«®è©¢é†«å¸«æˆ–è—¥å¸«äº†è§£è©³ç´°å»ºè­°ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å¯èƒ½å¼•èµ·ä½è¡€é‰€ï¼Œå½±éŸ¿å¿ƒè‡Ÿè—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šç›£æ¸¬é›»è§£è³ª


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Cerebrovascular Disorders** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**é’å…‰çœ¼** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šSystemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€²** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€²** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šDuring chronic administration, the clearance of beta-blockers that are primarily metabolized by the liver (e...

**é‡ç—‡è‚Œç„¡åŠ›** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šBeta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplop...

**Pheochromocytoma** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Psoriasis** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šThe use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis...

**å¿ƒæéé€Ÿ** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**æ°£å–˜** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šPatients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers...

**Atrioventricular Block** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚

**Shock, Cardiogenic** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

**å¿ƒè‡Ÿè¡°ç«­** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**ç³–å°¿ç—…** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€ç³–ã€‚

**Diseases requiring hemodialysis** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**Hypersensitivity** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šThe use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associa...

**Myocardial Ischemia** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Peripheral Vascular Diseases** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
Metoprolol å°æ…¢æ€§è‚ºå¿ƒç—…çš„é æ¸¬å…·æœ‰è‡¨åºŠç›¸é—œæ€§ã€‚å¤šé …é€²è¡Œä¸­çš„è‡¨åºŠè©¦é©—æ­£åœ¨è©•ä¼° beta-blocker åœ¨ COPD å’Œå¿ƒè¡°å…±ç—…æ‚£è€…ä¸­çš„æ•ˆç›Šå’Œå®‰å…¨æ€§ã€‚å‚³çµ±ä¸Šèªç‚º beta-blocker åœ¨ COPD ä¸­ç¦å¿Œï¼Œä½†è¿‘æœŸè­‰æ“šé¡¯ç¤ºé¸æ“‡æ€§ beta-1 é˜»æ–·åŠ‘å¯èƒ½å¸¶ä¾†æ·¨ç›Šè™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè¡€ç®¡å…±ç—…æ‚£è€…ä¸­ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç­‰å¾…é€²è¡Œä¸­è©¦é©—ï¼ˆå¦‚ NCT06825728, NCT03566667ï¼‰çµæœ
- ç¢ºå®š COPD åš´é‡ç¨‹åº¦èˆ‡æ²»ç™‚é¢¨éšª/æ•ˆç›Šçš„é—œä¿‚
- å»ºç«‹ COPD æ‚£è€…ä½¿ç”¨ beta-blocker çš„æœ€ä½³åŠ‘é‡ç­–ç•¥
- é–‹ç™¼é æ¸¬å“ªäº›æ‚£è€…æœ€å¯èƒ½å—ç›Šçš„ç”Ÿç‰©æ¨™è¨˜

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nefopam]({{ "/drugs/nefopam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Scopolamine]({{ "/drugs/scopolamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ethynodiol Diacetate]({{ "/drugs/ethynodiol_diacetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Loteprednol Etabonate]({{ "/drugs/loteprednol_etabonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caspofungin]({{ "/drugs/caspofungin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Metoprololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/metoprolol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_metoprolol,
  title = {Metoprololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/metoprolol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
